Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01044-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ada25&_hsenc=p2ANqtz-_LDS3egIvt3Yu3NsezjKslWC2IJqxY0iBFCTWlLHhYpeaiRNW2xVSs_-nzWabULh77g2HnVRfcofllJRZxlvjtOpsBkA&_hsmi=368028124&utm_content=368028124&utm_source=hs_email